Date | Price Target | Rating | Analyst |
---|---|---|---|
8/26/2024 | $13.00 | Buy | Rodman & Renshaw |
8/10/2023 | $6.00 | Outperform | RBC Capital Mkts |
Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00
RBC Capital Mkts initiated coverage of Cormedix with a rating of Outperform and set a new price target of $6.00
Needham reiterated coverage of Cormedix with a rating of Buy and set a new price target of $29.00 from $31.00 previously
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:CRMD) with a Buy and maintains $10 price target.
For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation
Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval
BERKELEY HEIGHTS, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024. Cantor Global Healthcare Conference Date: Thursday, September 19, 2024Time: 10:55AM EDTFormat: Fireside Chat and 1x1 MeetingsWebcast: Click Link A replay of the fireside chat will also be available in the "Events and Presentations" page on the i
BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath® (taurolidine and heparin) to its facilities in the US. The company, which provides healthcare services to more than 2,000 clinics in the United States, expects to initially target the utilization of DefenCath in up to 4,000 patients nationally, that would be prioritized based upon medical need. CorMedix received NDA approval of DefenCath under the
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports our initial partial quarter of sales since DefenCath's inpatient launch on April 15th. The Company reported net sales of $0.8 million for the second quarter, which primarily represents trade stocking for inpatient facilities. The company has started to see pull-through of units to inpati
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
10-Q - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
EFFECT - CorMedix Inc. (0001410098) (Filer)
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports our initial partial quarter of sales since DefenCath's inpatient launch on April 15th. The Company reported net sales of $0.8 million for the second quarter, which primarily represents trade stocking for inpatient facilities. The company has started to see pull-through of units to inpati
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, August 14th @ 8:30am ET Domestic:1-877-270-2148International:1-412-902-6510Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the pr
BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: On April 2, 2024, CMS published its HCPCS coding decision for DefenCath, establishing a new HCPCS Level II code for the product. CMS subsequently notified the Company on April 18th of its determination that DefenCath meets the criteria for a Transitional Drug Add-On Payment (TDAPA) and will be effective July 1, 2024. The TDAP